BE677918A - - Google Patents
Info
- Publication number
- BE677918A BE677918A BE677918DA BE677918A BE 677918 A BE677918 A BE 677918A BE 677918D A BE677918D A BE 677918DA BE 677918 A BE677918 A BE 677918A
- Authority
- BE
- Belgium
- Prior art keywords
- glucose
- insulin
- cortin
- membrane
- desc
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 23
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 229940125396 insulin Drugs 0.000 claims description 13
- 102000004877 Insulin Human genes 0.000 claims description 11
- 108090001061 Insulin Proteins 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000035939 shock Effects 0.000 claims description 5
- 208000026872 Addison Disease Diseases 0.000 claims description 4
- 208000010981 acute adrenal insufficiency Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 16
- 239000012528 membrane Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000000470 constituent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000001087 myotubule Anatomy 0.000 description 5
- 206010001367 Adrenal insufficiency Diseases 0.000 description 4
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000028161 membrane depolarization Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000010291 membrane polarization Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002336 repolarization Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000270936 Pelophylax esculentus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR14136A FR4396M (enExample) | 1965-04-22 | 1965-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE677918A true BE677918A (enExample) | 1966-09-01 |
Family
ID=8576965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE677918D BE677918A (enExample) | 1965-04-22 | 1966-03-16 |
Country Status (2)
| Country | Link |
|---|---|
| BE (1) | BE677918A (enExample) |
| FR (1) | FR4396M (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
-
1965
- 1965-04-22 FR FR14136A patent/FR4396M/fr not_active Expired
-
1966
- 1966-03-16 BE BE677918D patent/BE677918A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR4396M (enExample) | 1966-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pepato et al. | Cissus sicyoides (princess vine) in the long‐term treatment of streptozotocin‐diabetic rats | |
| Pratschke et al. | Brain death and its influence on donor organ quality and outcome after transplantation1 | |
| Panchal et al. | High-carbohydrate, high-fat diet–induced metabolic syndrome and cardiovascular remodeling in rats | |
| Sonksen et al. | Insulin: understanding its action in health and disease | |
| DiBona et al. | Maintenance of renal function in salt loaded rats despite severe tubular necrosis induced by HgCl2 | |
| Matveyenko et al. | β-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes | |
| Dokken | The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids | |
| Muneer et al. | Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model | |
| Schnuelle et al. | Perioperative fluid management in renal transplantation: a narrative review of the literature | |
| Ahmadiasl et al. | The anti-inflammatory effect of erythropoietin and melatonin on renal ischemia reperfusion injury in male rats | |
| Pontes Andersen et al. | Relationship between periodontitis and diabetes: lessons from rodent studies | |
| Sharma et al. | Macrophage metabolic rewiring improves heme-suppressed efferocytosis and tissue damage in sickle cell disease | |
| Yang et al. | Abrogation of adenosine A1 receptor signalling improves metabolic regulation in mice by modulating oxidative stress and inflammatory responses | |
| Jamiołkowska-Sztabkowska et al. | C-peptide and residual β-cell function in pediatric diabetes–state of the art | |
| Scagliola et al. | Venous congestion and systemic hypoperfusion in cardiorenal syndrome: Two sides of the same coin | |
| Jordan et al. | Cardiometabolic crosstalk in obesity-associated arterial hypertension | |
| Sartori et al. | Association between diastolic dysfunction with inflammation and oxidative stress in females ob/ob mice | |
| Iturriaga et al. | Carotid body chemoreception in the absence and presence of CO2HCO3− | |
| Malamud et al. | Hyperinsulinism and cerebral changes: report of a case due to an islet cell adenoma of the pancreas | |
| BE677918A (enExample) | ||
| Boschetti et al. | Aerobic Physical Exercise Improves Exercise Tolerance and Fasting Glycemia Independent of Body Weight Change in Obese Females | |
| CA3028101A1 (fr) | Kit destine au traitement du sepsis et/ou de toute hyper-inflammation generalisee (sirs) ou cellulaire dommageable | |
| Kwiatkowska et al. | Increased serum sodium values in brain-dead donor's influences its long-term kidney function | |
| WO2011004117A1 (fr) | Procédé et compositions pharmaceutiques pour le traitement de l'hyper glycémie post-prandiale du diabète de type ii par voie trans-muqueuse buccale | |
| Lefkowith et al. | Polyunsaturated fatty acids and renal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: LABORATOIRES LAROCHE NAVARRON Effective date: 19860316 |